A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 803
- 试验地点
- 96
- 主要终点
- Recommended dose for further study
研究概览
简要总结
This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.
详细描述
This study includes 3 parts: Phase 1 (pirtobrutinib monotherapy dose escalation and dose expansion), Phase 1b (pirtobrutinib combination therapy dose expansion), and Phase 2 (pirtobrutinib monotherapy dose expansion). In Phase 1, patients will be enrolled using an accelerated titration design. The starting dose of pirtobrutinib in oral tablet form is 25 mg/day (e.g., 25 mg once daily [QD]). Once the MTD and/or RP2D is identified in Phase 1 dose escalation, enrollment will continue to Phase 1 dose expansion and can commence to Phase 1b (Arms A and B). For Phase 2, patients will be enrolled to one of seven Phase 2 dose expansion cohorts depending on tumor histology and prior treatment history. Cycle length will be 28 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed CLL/SLL, WM, or NHL intolerant to either ≥ 2 prior standard of care regimens given in combination or sequentially OR have received 1 prior BTK inhibitor-containing regimen when a BTK inhibitor is approved as first line therapy (Phase 1) OR with prior treatment defined by phase 2 cohort (Phase 2 Patients only).
- •Adequate hematologic function (Phase 1 and 1b Patients only).
- •Responsive to transfusion support if given for thrombocytopenia or anemia (Phase 1 and 1b Patients only).
- •Histologically confirmed relapsed/recurrent CLL in whom venetoclax is appropriate standard salvage treatment; no prior venetoclax is permitted (Phase 1b Arm A Patients only).
- •Histologically confirmed relapsed/refractory CLL in whom venetoclax + rituximab is appropriate standard salvage treatment; no prior venetoclax is permitted (Phase 1b Arm B Patients only).
- •Eastern Cooperative Oncology Group (ECOG) 0-
- •Adequate hepatic and renal function.
- •Ability to receive study drug therapy orally.
- •Willingness of men and women of reproductive potential (defined as following menarche and not postmenopausal [and 2 years of non-therapy-induced amenorrhea] or surgically sterile) to observe conventional and effective birth control.
排除标准
- •Investigational agent or anticancer therapy within 5 half-lives or 14 days, whichever is shorter, prior to planned start of specified study therapy except antineoplastic and immunosuppressant monoclonal antibody treatment must be discontinued a minimum of 4 weeks prior to the first dose of pirtobrutinib. In addition, no concurrent systemic anticancer therapy is permitted.
- •Major surgery within 4 weeks prior to planned start of specified study therapy.
- •Radiotherapy with a limited field of radiation for palliation within 7 days of the first dose of study treatment.
- •Pregnancy or lactation.
- •Patients requiring therapeutic anticoagulation with warfarin.
- •Any unresolved toxicities from prior therapy greater than CTCAE (version 5.0) Grade 2 or greater at the time of starting study treatment except for alopecia.
- •History of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen receptor-modified T-cell (CAR-T) therapy within the past 60 days (180 days before the PK trigger) prior to planned start of specified study therapy.
- •Known central nervous system (CNS) involvement by systemic lymphoma. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible and enrolled to phase 2 Cohort 7 if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.
- •Active uncontrolled auto-immune cytopenia where new therapy introduced or concomitant therapy escalated within the 4 weeks prior to study enrollment is required to maintain adequate blood counts.
- •Clinically significant, uncontrolled cardiac, cardiovascular disease or history of myocardial infarction within 6 months prior to planned start of pirtobrutinib.
- •Active uncontrolled systemic bacterial, viral, fungal or parasitic infection.
- •Patients who have tested positive for human immunodeficiency virus (HIV) are excluded. For patients with unknown HIV status, HIV testing will be performed at Screening and result should be negative for enrollment.
- •Clinically significant active malabsorption syndrome.
- •Current treatment with certain strong CYP3A4 inhibitors or inducers and/or strong P-gp inhibitors.
- •For patients enrolled to phase 1b Arm A or B: Patients with prior treatment with venetoclax or other BCL-2 inhibitors.
- •Prior treatment with pirtobrutinib.
- •Active second malignancy unless in remission and with life expectancy > 2 years.
- •Known hypersensitivity to any component or excipient of pirtobrutinib.
- •For patients enrolled to phase 1b Arm B: Patients with prior significant hypersensitivity, allergy, or anaphylactic reaction to rituximab/biosimilar requiring discontinuation.
- •Patients with prior significant hypersensitivity to rituximab requiring discontinuation, prior allergic or anaphylactic reaction to rituximab (Phase 1b Arm B Patients only).
研究组 & 干预措施
Phase 2 (Pirtobrutinib Monotherapy) Cohort 3
CLL/SLL patients with no prior therapy.
干预措施: Pirtobrutinib (Drug)
Phase I Dose Escalation (Pirtobrutinib Monotherapy)
Dose Escalation and determination of MTD; multiple dose levels of pirtobrutinib to be evaluated
干预措施: Pirtobrutinib (Drug)
Phase 2 (Pirtobrutinib Monotherapy) Cohort 1
Non-blastoid MCL patients treated with a prior BTK-inhibitor containing regimen.
干预措施: Pirtobrutinib (Drug)
Phase 2 (Pirtobrutinib Monotherapy) Cohort 4
CLL/SLL patients treated with prior therapy, BTK inhibitor naïve.
干预措施: Pirtobrutinib (Drug)
Phase 2 (Pirtobrutinib Monotherapy) Cohort 2
CLL/SLL patients treated with 2 or more prior regimens, including a BTK inhibitor-containing regimen.
干预措施: Pirtobrutinib (Drug)
Phase 2 (Pirtobrutinib Monotherapy) Cohort 6
MZL patients treated with a prior BTK inhibitor-containing regimen.
干预措施: Pirtobrutinib (Drug)
Phase 2 (Pirtobrutinib Monotherapy) Cohort 5
WM patients treated with a prior BTK inhibitor-containing regimen.
干预措施: Pirtobrutinib (Drug)
Phase 1b Dose Expansion (Pirtobrutinib Combination Therapy) Arm B
Relapsed/Refractory CLL will receive the recommended Phase 2 dose of pirtobrutinib in combination with venetoclax and rituximab
干预措施: Pirtobrutinib (Drug)
Phase 2 (Pirtobrutinib Monotherapy) Cohort 7
Defined as CLL/SLL or NHL not otherwise specified in Cohorts 1 through 6, inclusive of CLL/SLL, Richter's transformation, or low grade NHL with transformation, blastoid MCL, and patients with history of CNS involvement or primary CNS lymphoma. In the event the Sponsor electively closes Cohorts 2-4 prior to completion, patients with CLL/SLL who are ineligible to participate in or unable to access late phase studies of pirtobrutinib may be eligible to enroll in this cohort Diffuse large B-cell lymphoma (DLBCL) is excluded. MCL without prior BTK inhibitor treatment is excluded. Patients enrolling to Cohort 7 must have received one or more prior therapies or have no available approved therapy with demonstrated clinical benefit with the exception of untreated Richter's transformation, which is allowed.
干预措施: Pirtobrutinib (Drug)
Phase 1b Dose Expansion (Pirtobrutinib Combination Therapy) Arm A
Relapsed/Refractory CLL will receive the recommended Phase 2 dose of pirtobrutinib in combination with venetoclax
干预措施: Pirtobrutinib (Drug)
Phase 1b Dose Expansion (Pirtobrutinib Combination Therapy) Arm A
Relapsed/Refractory CLL will receive the recommended Phase 2 dose of pirtobrutinib in combination with venetoclax
干预措施: Venetoclax (Drug)
Phase 1b Dose Expansion (Pirtobrutinib Combination Therapy) Arm B
Relapsed/Refractory CLL will receive the recommended Phase 2 dose of pirtobrutinib in combination with venetoclax and rituximab
干预措施: Venetoclax (Drug)
Phase 1b Dose Expansion (Pirtobrutinib Combination Therapy) Arm B
Relapsed/Refractory CLL will receive the recommended Phase 2 dose of pirtobrutinib in combination with venetoclax and rituximab
干预措施: Rituximab (Drug)
Phase 1 Dose Expansion (Pirtobrutinib Monotherapy)
Patients to receive the recommended Phase 2 dose of pirtobrutinib
干预措施: Pirtobrutinib (Drug)
结局指标
主要结局
Recommended dose for further study
时间窗: Up to 24 Months
Phase I
To assess the preliminary anti-tumor activity of pirtobrutinib based on ORR as assessed by an Independent Review Committee (IRC).
时间窗: Up to 24 months
Phase II
Maximum Tolerated Dose (MTD)
时间窗: Up to 24 Months
Phase I
To evaluate the safety of pirtobrutinib in combination with venetoclax and rituximab (Arm B) by assessing incidence and severity of treatment-emergent adverse events as determined by CTCAE v5.0
时间窗: Up to 24 Months
For Phase 1b
To evaluate the safety of pirtobrutinib in combination with venetoclax (Arm A) by assessing incidence and severity of treatment-emergent adverse events as determined by CTCAE v5.0
时间窗: Up to 24 Months
For Phase 1b
次要结局
- Overall survival (OS).(Up to 24 Months)
- Functional Response: Change from Baseline in Physical Functioning as Measured by Physical Functioning Scale from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Version 3.0 (EORTC QLQ)(Baseline, End of Treatment (Estimated Up to 24 Months))
- To determine the safety profile and tolerability of pirtobrutinib including acute and chronic toxicities by collecting and evaluating Adverse events and treatment emergent adverse events.(Up to 24 Months)
- To assess the preliminary anti-tumor activity of pirtobrutinib based on overall response rate (ORR) as assessed by investigator.(Up to 24 Months)
- ORR as assessed by the Investigator.(Up to 24 Months)
- Progression free survival (PFS) as assessed by the Investigator and IRC.(Up to 24 Months)
- Duration of response (DOR) as assessed by the Investigator and IRC.(Up to 24 Months)
- To assess the preliminary anti-tumor activity of pirtobrutinib in combination based on overall response rate (ORR) as assessed by investigator.(Up to 24 months)
- To determine the safety profile and tolerability of pirtobrutinib including acute and chronic toxicities by collecting and evaluating Adverse events and treatment emergent adverse events(Up to 24 Months)
- Symptomatic Response: Change from Baseline in Mantle Cell Lymphoma (MCL)-related symptoms selected from the European Organisation for Research and Treatment of Cancer (EORTC) Item Library(Baseline, End of Treatment (Estimated Up to 24 Months))
- To characterize the pharmacokinetics (PK) properties of pirtobrutinib by collecting and evaluating serum at protocol specified time points.(Up to 24 months)
- Best overall response (BOR) as assessed by the Investigator and IRC.(Up to 24 Months)
- To characterize the pharmacokinetics (PK) properties of pirtobrutinib by collecting and evaluating serum at protocol specified time points.(Up to 24 Months)